SB 202190 (hydrochloride)

SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity[1][2]. SB202190 hydrochloride induces autophagy[3].

Product Specifications

CAS Number

[350228-36-3]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; Autophagy; Organoid; p38 MAPK

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/sb-202190-hydrochloride.html

Purity

99.66

Solubility

DMSO : 83.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC1=CC=C(C2=NC(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)N2)C=C1.[H]Cl

Molecular Formula

C20H15ClFN3O

Molecular Weight

367.80

Precautions

H315, H319, H335

References & Citations

[1]Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351 (Pt 1) :95-105.|[2]Yang S, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013;2013:215798.